FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism.
Sign Up to like & getrecommendations! Published in 2020 at "Experimental eye research"
DOI: 10.1016/j.exer.2020.108107
Abstract: Pathological ocular angiogenesis commonly results in visual impairment or even blindness. Unveiling the mechanisms of pathological angiogenesis is critical to identify the regulators and develop effective targeted therapies. Here, we used corneal neovascularization (CNV) model… read more here.
Keywords: angiogenesis; fto regulates; ythdf2; ocular angiogenesis ... See more keywords
Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Drug Delivery Science and Technology"
DOI: 10.1016/j.jddst.2018.07.003
Abstract: Abstract Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) are the most common ocular diseases and a leading cause of blindness in American adults. Laser treatments and drug intervention with Ranibizumab, Aflibercept and Bevacizumab are… read more here.
Keywords: drug; drug delivery; treat ocular; ocular angiogenesis ... See more keywords
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2020.11056
Abstract: Ocular angiogenesis is a major cause of severe vision loss, which can affect several parts of the eye, including the retina, choroid and cornea. Vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors have demonstrated great… read more here.
Keywords: sklb1002 potent; angiogenesis; sklb1002 administration; ocular angiogenesis ... See more keywords